Los Angeles, CA -- (SBWIRE) -- 11/30/2018 -- This report studies the global Pulmonary Arterial Hypertension (PAH) market status and forecast, categorizes the global Pulmonary Arterial Hypertension (PAH) market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat.

The global Pulmonary Arterial Hypertension (PAH) market is valued at 5960 million US$ in 2017 and will reach 9970 million US$ by the end of 2025, growing at a CAGR of 6.7% during 2018-2025.

Request Sample Report Copy@ https://www.qyresearch.com/sample-form/form/509823/global-pulmonary-arterial-hypertension-pah-sales-market

The major players covered in this report

Actelion

Gilead Sciences

United Therapeutics

GlaxoSmithKline

Pfizer

Bayer

Arena

...

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

United States

Europe

China

Japan

Southeast Asia

India

Buy Full market Report Now, Report delivery time within 24 hours @ https://www.qyresearch.com/settlement/pre/62d7fc11f80ac65e1ce1ea287b68ebad,0,1,Global%20Pulmonary%20Arterial%20Hypertension%20PAH%20Sales%20Market%20Report%202018

About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.